"Maybe they could answer the question, is the 95th biosimilar switching trial likely to show something different to the previous 94?" asks UK oncologist Dr Paul Cornes. …
Latest Video
New Stories
-
Japanese pharma moves to acquire local stem cell company
July 22, 2019 - - Latest News -
Achieving greater transparency with no transparency
July 22, 2019 - - Latest News -
The parental leave experience at PAGE workshop
July 22, 2019 - - Latest News -
Not enough to secure streamlined authority
July 22, 2019 - - Latest News -
Greg Hunt confirms wider access to Kalydeco
July 22, 2019 - - Latest News -
Disappointment for Australian innovation
July 19, 2019 - - Latest News -
Boehringer Ingelheim acquires new oncology platform
July 19, 2019 - - Latest News